ReviewWorld journal of hepatology2023
Recent advances in recurrent hepatocellular carcinoma therapy.
Review in World journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- AKR1B10 as a serum marker for diagnosis and postoperative monitoring of hepatocellular carcinoma.British journal of cancer · 2026Article
- Prognostic impact of malnutrition based on the global leadership initiative on malnutrition criteria in older patients undergoing liver resection for hepatocellular carcinoma.Surgery today · 2026Article
- Stemness plasticity in hepatocellular carcinoma: spatial niches and therapeutic implications.Journal of liver cancer · 2026Article
- Early Recurrence of HCC Is Driven by Inflammation-Related HIF-1α Independent Angiogenesis Rather than Hypoxia-Induced Immune Escape.Biomolecules · 2026Article
- Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation.The Journal of biological chemistry · 2026Article
- Synergistic immunotherapeutic effects of irreversible electroporation and CAR-NK cell therapy against hepatocellular carcinoma.Signal transduction and targeted therapy · 2026Article
- Synthesis, characterization, antioxidant and anticancer potential of Kalanchoe pinnata green synthesized silver nanoparticles targeting p53/MDM2 nexus in hepatic cancer: integrated in vitro and in silico study.Scientific reports · 2026Article
- The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant.Cancers · 2026Article
- Machine Learning-Based Sialylation-Associated Gene Signature Predicts Prognosis and Immune Landscape in Hepatocellular Carcinoma: Validation via Multi-Omics Analysis and in vitro Assays.Journal of hepatocellular carcinoma · 2026Article
- Clinicopathological insights and management of liver metastases: Current advances and future perspectives.World journal of hepatology · 2025Review
- Leave No "Stone" Unturned: Biliary Obstruction From Isolated Intraductal Metastatic HCC.ACG case reports journal · 2025Article
- Article
- Machine learning-based integration reveals immunological heterogeneity and the clinical potential of T cell receptor (TCR) gene pattern in hepatocellular carcinoma.Apoptosis : an international journal on programmed cell death · 2025Article
- Overexpression of ORAOV1 and its association with immunotherapy resistance in hepatocellular carcinoma.PeerJ · 2025Article
- Access to Medical Research is a Basic Human Right: A Roadmap to Research Integration Into a Practical Hepatocellular Carcinoma Treatment Allocation Algorithm (HCC-TAA).Journal of hepatocellular carcinoma · 2025Article
- The role of transketolase in the immunotherapy and prognosis of hepatocellular carcinoma: a multi-omics approach.Frontiers in immunology · 2025Article
- Metabolic syndrome is associated with worse prognosis in elderly patients with hepatocellular carcinoma.Frontiers in oncology · 2025Article
- Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.Belitung nursing journal · 2025Article
- Circular RNA in hepatocellular carcinoma: emerging therapeutic strategies.Frontiers in immunology · 2025Review
- Pathologic complete response to conversion therapy in hepatocellular carcinoma using patient-derived organoids: A case report.World journal of gastrointestinal oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, accounting for 75%-85% of cases. Although treatments are given to cure early-stage HCC, up to 50%-70% of individuals may experience a relapse of the illness in the liver after 5 years. Research on the fundamental treatment modalities for recurrent HCC is moving significantly further. The precise selection of individuals for therapy strategies with established survival advantages is crucial to ensuring better outcomes. These strategies aim to minimize substantial morbidity, support good life quality, and enhance survival for patients with recurrent HCC. For individuals with recurring HCC after curative treatment, no approved therapeutic regimen is currently available. A recent study presented novel approaches, like immunotherapy and antiviral medication, to improve the prognosis of patients with recurring HCC with the apparent lack of data to guide the clinical treatment. The data supporting several neoadjuvant and adjuvant therapies for patients with recurring HCC are outlined in this review. We also discuss the potential for future clinical and translational investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.